Abzu, a CataloniaBio & HealthTech member, is one of 75 of Europe’s high-potential startups selected in the extremely competitive June cutoff of the 2022 European Innovation Council (EIC) Accelerator program.

The Danish and Spanish deep-tech startup is disrupting the pharmaceutical industry with its proprietary trustworthy artificial intelligence. Abzu will use this funding to further develop its discovery system Reason, a user-friendly and easy-to-operate platform built on Abzu’s QLattice engine. Abzu’s discovery engine, the QLattice, is a novel transparent and trustworthy AI algorithm that is as human-centric as it is high-performing. Reason will make the QLattice’s interpretable and explainable predictions widely accessible.

Now Abzu will be applying the €2.5 million grant to the development of its discovery system Reason, a user-friendly and easy-to-operate platform built on the QLattice engine that makes interpretable and explainable predictions widely accessible. The Abzoids look forward to a beta release of Reason in the first half of 2023.

“We want to be a big part of establishing Europe as a global hub for trustworthy AI. Our QLattice is already human-centric and trustworthy, and next year Reason will make explainable discoveries widely accessible,” says co-founder and CEO Casper Wilstrup.

More information

Photo: Part of the Abzu team in Barcelona.